CVS Health to replace J&J's Stelara with biosimilars
CVS Health will replace Johnson & Johnson's Stelara with lower-cost biosimilars starting July 1. Most members will pay $0 out-of-pocket for these therapies.
Xurve View
Insights:
Xurve View
CVS HEALTH CORP will remove JOHNSON & JOHNSON's psoriasis drug Stelara from its primary drug lists starting July 1. The pharmacy benefit unit will pivot to lower-cost biosimilars to reduce expenses for its health plan clients. This shift pressures high-margin biologics as cheaper alternatives gain traction in the specialty drug market.
